Earn CME credit for this activity: https://www.naccme.com/program/2018-802-04
This on-demand webcast examines the latest clinical and pharmacoeconomic data surrounding emerging therapies in AML, including novel chemotherapy formulations, FLT3 inhibitors, and IDH inhibitors for informed pathway placement.
© 2018 NACCME, an HMP Company